Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3319-3327

  Cai, Shanbao ^a   Xu, Yi ^a   Cooper, Ryan J ^a   Ferkowiez, Michael J ^a   Hartwell, Jennifer R ^a   Pollok, Karen E ^a   Kelley, Mark R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CD34 ANTIGEN; MESYLIC ACID METHYL ESTER; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ARTICLE; CELL KILLING; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; DNA ALKYLATION; DNA DAMAGE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL;

EID: 17144431814     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3335     Document Type: Article

References (53)

1. Wadhwa PD, Zielske SP, Roth JC, Ballas CB, Bowman JE, Gerson SL Cancer gene therapy: scientific basis. Annu Rev Med 2002;53:437-52.
2. Hansen WK, Kelley, MR. Review of mammalian DNA repair and translational implications. J Pharmacol Exp Ther 2000;295:1-9.
3. Friedberg EC, Walker GC, Siede W. DNA repair and mutagenesis, Washington, D.C.: ASM Press; 1995.
4. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
5. 6-methylguanine-DNA methyltransferase and chloroethylnitrosourea-treated DNA. Cancer Res 1992;52:6052-8.
6. Erickson LC, Laurent G, Sharkey NA, Kohn KW. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature 1980;288:727-9.
7. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4:296-307.
8. Nagasubramanian R, Dolan ME. Temozolomide: realizing the promise and potential. Curr Opin Oncol 2003;15:412-8.
9. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994;33:9045-51.
10. Liu L, Yan L, Donze JR, Gerson SL. Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. Mol Cancer Ther 2003;2:1061-6.
11. 6-methylguanine DNA methyltransferase (MGMT) and AP endonuclease (APE/redox effector factor 1 (Ref 1)) DNA repair proteins. J Biol Chem 1998;273:756-62.
12. Limp-Foster M, Kelley MR. DNA repair and gene therapy: implications for translational uses. Environ Mol Mutagen 2000;35:71-81.
13. Dobson AW, Kelley MR, Wilson GL, LeDoux SP. Targeting DNA repair proteins to mitochondria. Methods Mol Biol 2002;197:351-62.
14. LeDoux SP, Driggers WJ, Hollensworth BS, Wilson GL. Repair of alkylation and oxidative damage in mitochondrial DNA. Mutat Res 1999;434:149-59.
15. Bohr VA. Mitochondrial DNA repair. Prog Nucleic Acid Res Mol Biol 2001;68:255-6.
16. Bohr VA, Anson RM. Mitochondrial DNA repair pathways. J Bioenerg Biomembr 1999;31:391-8.
17. Roth TJ, Xu Y, Luo M, Kelley MR. Human-yeast chimeric repair protein protects mammalian cells against alkylating agents: enhancement of MGMT protection. Cancer Gene Ther 2003;10:603-10.
18. Kreklau EL, Limp-Foster M, Liu N, Xu Y, Kelley MR, Erickson LC. A novel fluorometric oligonucleotide assay to measure O(6)-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing methylpurine DNA glycosylase. Nucleic Acids Res 2001;29:2558-66.
19. Fishel ML, Seo YR, Smith ML, Kelley MR. Imbalancing the DNA base excision repair pathway in the mitochondria: targeting and overexpressing N-methylpurine DNA glycosylase in mitochondria leads to enhanced cell killing. Cancer Res 2003;63:608-15.
20. Dobson AW, Xu Y, Kelley MR, LeDoux SP, Wilson GL. Enhanced mitochondrial DNA repair and cellular survival after oxidative stress by targeting the human 8-oxoguanine glycosylase repair enzyme to mitochondria [in process citation]. J Biol Chem 2000;275:37518-23.
21. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. Biochem Biophys Res Commun 1996;226:561-5.
22. Kobune M, Xu Y, Baum C, Kelley MR, Williams DA. Retrovirus-mediated expression of the base excision repair proteins, formamidopyrimidine DNA glycosylase or human oxoguanine DNA glycosylase, protects hematopoietic cells from N,N′,N-triethylenethiophosphoramide (thioTEPA)-induced toxicity in vitro and in vivo. Cancer Res 2001;61:5116-25.
23. He YH, Xu Y, Kobune M, Wu M, Kelley MR, Martin WJ II. Escherichia coli FPG and human OGG1 reduce DNA damage and cytotoxicity by BCNU in human lung cells. Am J Physiol Lung Cell Mol Physiol 2002;282:L50-5.
24. Pollok KE, Hartwell JR, Braber A, et al. In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Hum Gene Ther 2003;14:1703-14.
25. Cheng L, Du C, Lavau C, et al. Sustained gene expression in retrovirally transduced, engrafting human hematopoietic stem cells and their lympho-myeloid progeny. Blood 1998;92:83-92.
26. Ragg S, Xu-Welliver M, Bailey J, et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 2000;60:5187-95.
27. Hildinger M, Abel KL, Ostertag W, Baum C. Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol 1999;73:4083-9.
28. Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, Eiden MV. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991;65:2220-4.
29. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 2004;3:679-86.
30. 6-methylguanine DNA methyltransferase (MGMT/AGT) to the mitochondria affords protection against BCNU, temozolomide and MMS. Cancer Gene Ther 2003;10:76.
31. Druzhyna NM, Hollensworth SB, Kelley MR, Wilson GL, Ledoux SP. Targeting human 8-oxoguanine glycosylase to mitochondria of oligodendrocytes protects against menadione-induced oxidative stress. Glia 2003;42:370-8.
32. Dobson AW, Grishko V, LeDoux SP, Kelley MR, Wilson GL, Gillespie MN. Enhanced mtDNA repair capacity protects pulmonary artery endothelial cells from oxidant-mediated death. Am J Physiol Lung Cell Mol Physiol 2002;283:L205-10.
33. 6- methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Hum Gene Ther 1999;10:2769-78.
34. Kaina B, Ochs K, Grosch S, et al. BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis. Prog Nucleic Acid Res Mol Biol 2001;68:41-54.
35. 6-alkylguanine in cell killing and mutagenesis in Chinese hamster ovary cells. Carcinogenesis 1991;12:83-9.
36. 6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther 2001;3:78-87.
37. Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest 2003;112:1561-70.
38. Davis BM, Humeau L, Dropulic B. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol Ther 2004;9:160-72.
39. Maze R, Kapur R, Kelley MR, Hansen WK, Oh SY, Williams DA. Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine DNA methyltransferase complementary DNA. J Immunol 1997;158:1006-13.
40. 6-benzylguanine sensitization to chloroethylnitrosourea treatment. J Pharmacol Exp Ther 1999;290:1467-74.
41. Barvaux VA, Ranson M, Brown R, McElhinney RS, McMurry TB, Margison GP. Dual repair modulation reverses temozolomide resistance in vitro. Mol Cancer Ther 2004;3:123-7.
42. Pagani E, Pepponi R, Fuggetta MP, et al. DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system. J Chemother 2003;15:173-83.
43. Brada M. NICE verdict on temozolomide: where next? Br J Cancer 2002;86:499-500.
44. LeDoux SP, Wilson GL, Beecham EJ, Stevnsner T, Wassermann K, Bohr VA. Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells. Carcinogenesis 1992;13:1967-73.
45. Myers KA, Saffhill R, O'Connor PJ. Repair of alkylated purines in the hepatic DNA of mitochondria and nuclei in the rat. Carcinogenesis 1988;9:285-92.
46. 6-ethylguanine from mitochondrial DNA in rat tissues exposed to N-ethyl-N-nitrosourea in vivo. J Biol Chem 1988;263:6854-6.
47. LeDoux SP, Wilson GL. Base excision repair of mitochondrial DNA damage in mammalian cells. Prog Nucleic Acid Res Mol Biol 2001;68:273-84.
48. Grishko VI, Druzhyna N, LeDoux SP, Wilson GL. Nitric oxide-induced damage to mtDNA and its subsequent repair. Nucleic Acids Res 1999;27:4510-6.
49. Ledoux SP, Shen CC, Grishko VI, Fields PA, Gard AL, Wilson GL. Glial cell-specific differences in response to alkylation damage. Glia 1998;24:304-12.
50. de Souza-Pinto NC, Bohr VA. The mitochondrial theory of aging: involvement of mitochondrial DNA damage and repair. Int Rev Neurobiol 2002;53:519-34.
51. Hudson EK, Hogue BA, Souza-Pinto NC, et al. Age-associated change in mitochondrial DNA damage. Free Radic Res 1998;29:573-9.
52. Dang CV Gerson SL, Litwak M, Padarathsingh M. Gene therapy and translational cancer research. Clin Cancer Res 1999;5:471-4.
53. Moritz T, Williams DA. Transfer of drug resistance genes to hematopoietic precursors. In: Encyclopedia of cancer. New York: Academic Press; 1997. p. 1765-76.